Protein kinase C alpha, Protein kinase C beta, and Fibrinogen (PKCα/PKCβ/Fibrinogen)

Protein kinase C (PKC) alpha and beta are serine/threonine kinases that serve as critical mediators in the intracellular signaling cascades of platelets and vascular cells (UniProt P17252, P05771). Fibrinogen is a hexameric plasma glycoprotein that is converted into insoluble fibrin by thrombin and acts as the primary ligand for the platelet integrin receptor alpha-IIb/beta-3 (UniProt P02671). The interaction between these molecules is central to hemostasis; PKC activation is required for inside-out signaling that enables high-affinity fibrinogen binding, while fibrinogen binding itself triggers outside-in signaling that further activates PKC to stabilize the thrombus (PMID: 20109033). Dysregulation of this axis is a major driver of pathological thrombosis, leading to conditions such as myocardial infarction and stroke. Therapeutic strategies include the use of PKC inhibitors like ruboxistaurin to treat vascular complications or fibrinogen-receptor antagonists like abciximab to prevent acute clotting (PubChem). This entry is considered incorrect as a single target because it combines multiple distinct molecular entities—two enzymes and a structural protein—into a functional pathway rather than a single druggable receptor or enzyme.

Other names

PRKCAPRKCBFGAFGBFGGPKC-alphaPKC-betaFibrinogen complexPlatelet PKC-fibrinogen axis

Inhibition of PKC alpha and beta isoforms prevents the intracellular inside-out signaling required for the conformational activation of the integrin alpha-IIb/beta-3 receptor, thereby reducing its affinity for fibrinogen and preventing platelet aggregation. Alternatively, fibrinogen-receptor antagonists directly block the binding of fibrinogen to the activated integrin on the platelet surface.